Ameriprise’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-25,869
| Closed | -$135K | – | 3983 |
|
|
2023
Q4 | $135K | Sell |
25,869
-231,611
| -90% | -$2.29M | ﹤0.01% | 3781 |
|
|
2023
Q3 | $4.06M | Sell |
257,480
-8,937
| -3% | -$161K | ﹤0.01% | 2446 |
|
|
2023
Q2 | $5.18M | Buy |
266,417
+68,609
| +35% | +$1.63M | ﹤0.01% | 2320 |
|
|
2023
Q1 | $5.61M | Sell |
197,808
-5,517
| -3% | -$164K | ﹤0.01% | 2241 |
|
|
2022
Q4 | $5.94M | Sell |
203,325
-8,116
| -4% | -$258K | ﹤0.01% | 2168 |
|
|
2022
Q3 | $5.59M | Sell |
211,441
-41,460
| -16% | -$1.52M | ﹤0.01% | 2132 |
|
|
2022
Q2 | $11.2M | Sell |
252,901
-11,821
| -4% | -$543K | ﹤0.01% | 1647 |
|
|
2022
Q1 | $13.1M | Sell |
264,722
-2,334
| -0.9% | -$112K | ﹤0.01% | 1678 |
|
|
2021
Q4 | $13.6M | Buy |
267,056
+108,600
| +69% | +$5.63M | ﹤0.01% | 1719 |
|
|
2021
Q3 | $8.84M | Buy |
158,456
+7,652
| +5% | +$376K | ﹤0.01% | 1954 |
|
|
2021
Q2 | $6.46M | Buy |
150,804
+30,104
| +25% | +$1.24M | ﹤0.01% | 2268 |
|
|
2021
Q1 | $5.04M | Buy |
120,700
+11,573
| +11% | +$537K | ﹤0.01% | 2393 |
|
|
2020
Q4 | $5.08M | Buy |
109,127
+2,935
| +3% | +$137K | ﹤0.01% | 2264 |
|
|
2020
Q3 | $4.51M | Buy |
106,192
+20,470
| +24% | +$895K | ﹤0.01% | 2153 |
|
|
2020
Q2 | $4.11M | Sell |
85,722
-71
| -0.1% | -$3.54K | ﹤0.01% | 2204 |
|
|
2020
Q1 | $3.95M | Sell |
85,793
-215
| -0.2% | -$10.8K | ﹤0.01% | 2065 |
|
|
2019
Q4 | $5.17M | Sell |
86,008
-1,245
| -1% | -$74.2K | ﹤0.01% | 2216 |
|
|
2019
Q3 | $4.94M | Sell |
87,253
-7,760
| -8% | -$436K | ﹤0.01% | 2213 |
|
|
2019
Q2 | $5.29M | Buy |
95,013
+36,760
| +63% | +$1.92M | ﹤0.01% | 2219 |
|
|
2019
Q1 | $2.94M | Sell |
58,253
-4,582
| -7% | -$204K | ﹤0.01% | 2546 |
|
|
2018
Q4 | $2.53M | Sell |
62,835
-1,005
| -2% | -$51.8K | ﹤0.01% | 2538 |
|
|
2018
Q3 | $4.43M | Buy |
63,840
+16,840
| +36% | +$1.28M | ﹤0.01% | 2412 |
|
|
2018
Q2 | $3.56M | Sell |
47,000
-78,284
| -62% | -$4.92M | ﹤0.01% | 2460 |
|
|
2018
Q1 | $6.6M | Buy |
125,284
+910
| +0.7% | +$52.9K | ﹤0.01% | 1973 |
|
|
2017
Q4 | $6.64M | Sell |
124,374
-14,245
| -10% | -$793K | ﹤0.01% | 1922 |
|
|
2017
Q3 | $8.27M | Buy |
138,619
+5,548
| +4% | +$336K | ﹤0.01% | 1727 |
|
|
2017
Q2 | $10.5M | Buy |
133,071
+18,335
| +16% | +$1.5M | 0.01% | 1517 |
|
|
2017
Q1 | $9.52M | Sell |
114,736
-4,921
| -4% | -$366K | ﹤0.01% | 1567 |
|
|
2016
Q4 | $9.49M | Buy |
119,657
+10,694
| +10% | +$777K | 0.01% | 1569 |
|
|
2016
Q3 | $7.63M | Buy |
+108,963
| New | +$6.04M | ﹤0.01% | 1664 |
|
|
2016
Q1 | – | Sell |
-25,846
| Closed | -$2.29M | – | 3890 |
|
|
2015
Q4 | $2.29M | Buy |
25,846
+1,465
| +6% | +$116K | ﹤0.01% | 2524 |
|
|
2015
Q3 | $1.8M | Buy |
24,381
+5,382
| +28% | +$448K | ﹤0.01% | 2675 |
|
|
2015
Q2 | $1.54M | Buy |
18,999
+347
| +2% | +$22.6K | ﹤0.01% | 2905 |
|
|
2015
Q1 | $781K | Buy |
+18,652
| New | +$529K | ﹤0.01% | 3038 |
|
Other funds holding EGRX
NCM
ACM
JGC
Ameriprise's EGRX Position: Q1 2024 in Review
Ameriprise sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 25,869 shares — an estimated $135K sold.
Ameriprise first reported a position in EGRX in Q1 2015 and held it in 34 quarters. The position peaked at $13.6M in Q4 2021. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.
- Ameriprise reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
- Ameriprise sold 25,869 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $135K.
- Ameriprise first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 34 quarters.
- Ameriprise's Eagle Pharmaceuticals, Inc. position peaked at $13.6M in Q4 2021.
- 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.
Based on Ameriprise's 13F filing for Q1 2024, filed 15 May 2024.